News & Analysis
Will Mesoblast recover from Teva & Celgene setbacks?
Will Mesoblast recover from Teva & Celgene setbacks?

Australian Regenerative Medicine company Mesoblast recently suffered a significant financial setback in the ongoing development of MPC-150-IM, their experimental Phase III treatment for chronic heart failure, with their key US

News & Analysis
Texcell acquisition of Vivo Science underscores the shifting Biopharma Contract Services landscape
Texcell acquisition of Vivo Science underscores the shifting Biopharma Contract Services landscape

Texcell, a French provider of biosafety contract services, recently acquired German company Vivo Science GmbH, a GLP/GMP compliant contract research test facility specialising in toxicology, immunology & virology in vivo

News & Analysis
Thermo Fisher to Acquire FEI Company for $4.2B
Thermo Fisher to Acquire FEI Company for $4.2B

Thermo Fisher Scientific have further cemented their reputation as a serial acquirer with the purchase of FEI Company for approximately $4.2B in cash. Oregon-based FEI Company are world leaders in

News & Analysis
Further AgriBusiness Consolidation as Bayer Makes a $62B Bid for Monsanto
Further AgriBusiness Consolidation as Bayer Makes a $62B Bid for Monsanto

Last week German multinational Bayer put forward an all-cash $62B bid for American AgTech giant Monsanto, further emphasizing the unprecedented period of consolidation that the global AgriBusiness market is currently

News & Analysis
Cell Therapy Ltd grants Japanese Licence for its Heart Regeneration Medicine to Daiichi Sankyo
Cell Therapy Ltd grants Japanese Licence for its Heart Regeneration Medicine to Daiichi Sankyo

Welsh stem cell company Cell Therapy Ltd. has granted Japanese drugmaker Daiichi Sankyo a license for Heartcel™, its promising cardiac regeneration medicine. Under the conditions of the deal, Daiichi Sankyo

News & Analysis
Evolution M&A Analysis: Evaluating Potential Acquisition Targets for Thermo Fisher Scientific
Evolution M&A Analysis: Evaluating Potential Acquisition Targets for Thermo Fisher Scientific

A recent mixed securities shelf registration filing by Thermo Fisher Scientific has prompted speculation from industry insiders and investors, with prominent advisors predicting further acquisitions for the company throughout 2016

Evolution Infographics
Evolution Infographic: The Rise & Diversification of Biologics
Evolution Infographic: The Rise & Diversification of Biologics

For our latest Data Visualisation project, the Evolution Global Team analysed historical new drug approval statistics and the current clinical trials pipeline to identify trends that highlight the rise and

News & Analysis
Evolution M&A Analysis: China seeks food security with $43 billion bid for Syngenta
Evolution M&A Analysis: China seeks food security with $43 billion bid for Syngenta

China made its boldest overseas takeover move yet this week, announcing that state-owned company ChemChina has submitted a $43 billion bid for Swiss seeds and pesticides group Syngenta with the

News & Analysis
To CRISPR or not to CRISPR: The Ongoing Ethical Debate Surrounding Embryonic Gene Editing
To CRISPR or not to CRISPR: The Ongoing Ethical Debate Surrounding Embryonic Gene Editing

The UK’s Human Fertilisation and Embryology Authority (HFEA) has given the go-ahead for a select group of Francis Crick Institute researchers to edit the genomes of human embryos. The group,

News & Analysis
Evolution Analysis: ACD Bio & Leica Biosystems Expand RNAscope Diagnostics Partnership
Evolution Analysis: ACD Bio & Leica Biosystems Expand RNAscope Diagnostics Partnership

Advanced Cell Diagnostics and Leica Biosystems have announced a comprehensive partnership to develop and commercialise tissue-based diagnostic tests based on ACD’s RNAscope in situ hybridisation (ISH) assays and Leica’s clinical

News & Analysis
Evolution M&A Analysis: Thermo Fisher to Acquire Affymetrix for $1.3 billion
Evolution M&A Analysis: Thermo Fisher to Acquire Affymetrix for $1.3 billion

Thermo Fisher Scientific (NYSE:TMO) have announced an agreement to acquire Affymetrix (NASDAQ:AFFX) for approximately $1.3 billion, or $14.00 per share, in cash. The acquisition was unanimously approved by the boards

News & Analysis
The Role of Metagenomic Analysis in Drug Development
The Role of Metagenomic Analysis in Drug Development

In recent years Next Generation Sequencing instrumentation has become much more accurate, efficient and affordable, enabling researchers to collect, sequence and analyse genomes with increasing ease. Consequently researchers are developing